Enzymatica AB (publ)

Capital Structure and Liquidity Enzymatica maintains a strong liquidity position with SEK 33.13 million in cash and equivalents, representing 22.6% of total assets. The company's price-to-book ratio of 5.55 suggests a premium valuation relative to its tangible book value. Despite a negative operating income of SEK -51.37 million, the company's low debt-to-equity ratio of 0.01 indicates minimal leverage risk. ### Profitability and Returns Enzymatica's profitability metrics are underperforming relative to industry norms. The company reported a net loss of SEK -51.89 million, resulting in a negative return on equity of -41.79% and a return on assets of -36.55%. These figures fall significantly below the typical performance of pharmaceutical firms, which generally exhibit positive returns on equity and assets. ### Segments and Geographic Exposure The company's revenue is concentrated in a single business segment focused on enzyme-based products for industrial applications. Geographic exposure is not disclosed in the available data, but the company is headquartered in Sweden, suggesting a potential regional concentration risk. ### Growth Trajectory Enzymatica's revenue of SEK 53.90 million reflects a challenging operating environment, with a gross profit of SEK 33.13 million. The company's free cash flow of SEK -46.72 million indicates ongoing cash burn, which may constrain growth initiatives unless offset by new product launches or strategic partnerships. ### Risk Factors The company faces moderate liquidity risk due to its negative operating cash flow of SEK -40.97 million, but its strong cash reserves mitigate immediate concerns. Dilution risk is assessed as low, with no immediate filing-based flags detected. The company's capital expenditure of SEK -231,000 is minimal, suggesting a conservative approach to asset investment. ### Recent Events No recent filings or transcripts have been identified that would indicate significant changes in the company's strategic direction or financial health.